In PEL, the unique cytogenetic and molecular genetic characteristics might suggest therapeutic targets beyond TP53; and its invariable association with biallelic TP53 alterations, implies an even worse diagnosis, compared to single-hit TP53 abnormalities. This evidence concerns the gene TP53 and primary effusion lymphoma.